ASCO 2016 Breast Cancer Review
-
Upload
osuccc-james -
Category
Healthcare
-
view
918 -
download
1
Transcript of ASCO 2016 Breast Cancer Review
-
The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
ASCO Annual Meeting 2016 Breast Cancer Robert Wesolowski, MD June 18, 2016
-
Disclosures Chair or Data Safety Monitoring Board for Helsinn, Inc Advisory Board member for Agenus, Inc Advisory Board member for Novartis (Afinitor) 2016
2
-
Highlights Extending aromatase inhibitor beyond 5 years:
MA17R Study (Plenary Session) Addition of palbociclib to endocrine therapy for
untreated metastatic breast cancer: Paloma 2 Study Novel CDK 4/6 inhibitor (abemaciclib): Monarch 2
Study Role of anthracycline regimen in adjuvant
chemotherapy: ABC Trial
3
-
Adjuvant Tamoxifen and Recurrence of ER(+) Breast Cancer
Early Breast Cancer Trialists Collaborative Group (EBCTCG) Lancet 2011; 378: 77184
-
Pooled analysis ATLAS + aTTom:Breast Cancer Mortality
-
Slide 5
Presented By Paul Goss at 2016 ASCO Annual Meeting
-
MA.17R Trial Schema and Design AI x 5 yrs - Following Prior 5 years of AI - preceded or not by Tamoxifen
Presented By Paul Goss at 2016 ASCO Annual Meeting
-
MA.17R Hypothesis and Objectives Does extending AI therapy from 5 to 10 years further
improve patient outcomes? Primary Objective: Disease Free Survival (from randomization to recurrence or
development of contralateral breast cancer (CBC), whichever came first)
Secondary Objectives: Overall Survival All CBC Safety Quality of life
8
-
Slide 11
Presented By Paul Goss at 2016 ASCO Annual Meeting
-
Presented By Paul Goss at 2016 ASCO Annual Meeting
-
MA.17R - DFS by pre-specified subgroups
Presented By Paul Goss at 2016 ASCO Annual Meeting
-
Presented By Paul Goss at 2016 ASCO Annual Meeting
-
Slide 17
Presented By Paul Goss at 2016 ASCO Annual Meeting
-
Conclusion First study to show benefit of extending AI beyond 5 years
resulting in 34% reduction in disease recurrences No worsening of QOL No new toxicities Bone health remains an important risk/benefit consideration AI are readily accessible around the world
14
-
CDK 4/6 Inhibitors
15
-
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
PALOMA-2: Primary Results From a Phase 3 Trial of Palbociclib Plus Letrozole Compared With Placebo Plus Letrozole in Postmenopausal Women With ER+/HER2 Advanced Breast Cancer
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Slide 14
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Hematologic AEs All Causality
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Non-hematologic AEs Occurring in 15% of Pts - All Causality
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Consistent Clinical Benefit Seen Across PALOMA Studies
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
Presented By Richard Finn at 2016 ASCO Annual Meeting
-
MONARCH 1Results from a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic disease.
Presented By Maura Dickler at 2016 ASCO Annual Meeting
-
Abemaciclib is a Selective Inhibitor of CDK4 & 6
Presented By Maura Dickler at 2016 ASCO Annual Meeting
-
MONARCH 1: Phase 2 Study Design
Presented By Maura Dickler at 2016 ASCO Annual Meeting
-
MONARCH 1: Response Summary
Presented By Maura Dickler at 2016 ASCO Annual Meeting
-
MONARCH 1: Treatment Duration
Presented By Maura Dickler at 2016 ASCO Annual Meeting
-
MONARCH 1: Most Common Adverse Events
Presented By Maura Dickler at 2016 ASCO Annual Meeting
-
Adjuvant Chemotherapy
33
-
US Oncology 9735 Study; 7 year follow up.
34
Jones et al. J Clin Oncol 2009; 27:1177-83
-
Background 10 year mortality is reduced by ~30% with anthracycline and taxane
containing regimen vs. no chemotherapy. 8 year mortality is further reduced by adding a taxane to anthracyclines
(RR=0.86; 95% CI 0.79-0.93). Cardiac mortality increased by ~56% with anthracyclines (RR 1.56,
2p=0.02) Increased risk of acute leukemia with anthracycline regimens (~1/200
patients) Would TC regimen provide similar benefit to anthracycline and taxane
regimen but spare patients long therm cardiac toxicity and risk of AML?
35
Lancet 2012;379:432-444
-
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
Timeline and Accrual of ABC Trials
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
Statistical Plan for ABC Trials
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
Statistical Plan for ABC Trials
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
ABC TrialsPatient Characteristics % all Patients
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
Results of Interim Analysis of ABC Trials
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
ABC Trials: Invasive Disease Free Survival
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
Forest Plot of IDFS By Stratification Variables
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
Slide 17
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
ABC Trials: First IDFS Events (N)
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
ABC Trials: Overall Survival
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
Conclusions
Presented By Joanne Blum at 2016 ASCO Annual Meeting
-
Rate Of Stomatitis in Everolimus Treated Patients
Bolero-2 Dexamethasone study
Number receiving Everolimus 485 92*
G1 Stomatitis 26% 17.4%
G2 Stomatitis 33% 2.4%
G3 Stomatitis 8% 0%
48
10 mL of commercially available 0.5 mg/5 mL dexamethasone oral solution to swish x 2 min, and spit QID for 8 wks,
*86 patients were available for efficacy
Rugo et al. Abstract 525
-
Thank You Questions?
49